Taiho Oncology Inc.

• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 Phase III 9 countries CARBOPLATIN; CISPLATIN; PEMETREXED; ZIPALERTINIB
• An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib Study Recruiting
  2024-512217-40-00 Phase II/III 4 countries FUTIBATINIB
• A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Recruiting
  2022-500391-62-00 Phase I/II 5 countries DECITABINE, CEDAZURIDINE; TOLINAPANT LACTATE
• A Study of ASTX030 (Cedazuridine in Combination with Azacitidine) in MDS, CMML, or AML Recruiting
  2024-515098-93-00 Phase III 7 countries AZACITIDINE; AZACITIDINE, CEDAZURIDINE
• An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced… Recruiting
  2023-503865-48-00 Phase II 4 countries DEXTROMETHORPHAN; DIGOXIN; MIDAZOLAM; ROSUVASTATIN; ZIPALERTINIB
• FOENIX-CCA4 Recruiting
  2023-503665-39-00 Phase II 4 countries FUTIBATINIB
• Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment Recruiting
  2024-516291-16-00 Phase I (Other) 5 countries
• Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors Ended
  2023-507516-12-00 Phase II 3 countries FOLINIC ACID; FUTIBATINIB; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; PEMBROLIZUMAB
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma… Ended
  2023-503575-21-00 Phase III 10 countries CARBOPLATIN; CISPLATIN; PEMETREXED; ZIPALERTINIB
• A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML Ended
  2024-516294-78-00 Phase II 1 country DECITABINE, CEDAZURIDINE; VENETOCLAX
• Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 Ended
  2024-516293-29-01 Phase II 8 countries DECITABINE, CEDAZURIDINE
• Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment Ended
  2024-516292-33-00 Phase I (Other) 5 countries
• A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations Ended
  2022-502595-23-00 Phase I (FiH) 5 countries TAS3351
• A study to investigate the effect of ASTX660 (tolinapant) on the pharmacokinetics of substrates of OCT1, OCT2, and MATE1 in healthy voluntee… Ended
  2023-503742-31-00 Phase I (Other) 1 country
• A PHASE 1 STUDY TO ASSESS THE MASS BALANCE, PHARMACOKINETICS, AND METABOLISM OF ORAL [14C]-ZIPALERTINIB IN HEALTHY ADULT MALE SUBJECTS Ended
  2023-505085-28-00 Phase I (Other) 1 country [14C]ZIPALERTINIB
• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer Ended
  2023-506922-35-00 Phase I 1 country
• A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Interm… Ended
  2024-516296-32-00 Phase I (Other) 3 countries DECITABINE; DECITABINE, CEDAZURIDINE
• A Phase 2 Study Evaluating Futibatinib (TAS-120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic bladder, urethra or pelvis ca… Ended
  2024-513760-26-00 Phase II 1 country FUTIBATINIB; PEMBROLIZUMAB
• A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors Ended
  2024-515175-35-00 Phase I 4 countries
• Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers. Ended
  2024-516679-33-00 Phase I (FiH) 2 countries TOLINAPANT LACTATE

Showing 1–20 of 20 trials